The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | CD70-targeted CAR T-cells for high-risk myeloma after BCMA CAR-T relapse
Arun Wiita, MD, PhD, University of California, San Francisco, CA, discusses the rationale and preclinical development of optimized CD70-targeted CAR T-cells as a potential therapy for high-risk myeloma following BCMA CAR-T relapse. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
